Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine, the pharmaceutical company said in a filing with the Taipei Exchange yesterday.
The company yesterday delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say when the regulator would complete its review, the filing showed.
The TGA in November last year gave the Medigen vaccine a provisional determination, the first step to provisional approval, corporate data showed.
Photo: CNA
The step allows for provisional registration of medicines on the basis of preliminary clinical data.
The TGA said it requires comprehensive non-clinical data on safety, quality and compliance with “good manufacturing practice,” the same as for prescription medicine.
The TGA is one of the world’s most credible regulatory authorities as defined by the WHO, Medigen said in the filing.
The COVID-19 vaccines from AstraZeneca PLC, Moderna Inc, Pfizer Inc and BioNTech SE, Johnson & Johnson, and Novavax Inc have obtained provisional approvals from the TGA.
Medigen’s COVID-19 vaccine has been given emergency use authorization in Taiwan and Paraguay, and the company is waiting for a review to be completed in the Kingdom of Eswatini, while New Zealand, Palau, Indonesia, Belize and Thailand exempt travelers who have received the vaccine without requiring strict quarantine measures, it said.
Medigen reported a net loss of NT$140 million (US$4.76 million) in the first quarter, or losses per share of NT$0.66.
First-quarter revenue advanced to NT$326 million from NT$3 million a year earlier, with gross margin of 64 percent.
The company’s operating expenses grew 27.5 percent annually to NT$361 million last quarter due to higher marketing and research spending, company data showed.
UNCERTAINTY: Investors remain worried that trade negotiations with Washington could go poorly, given Trump’s inconsistency on tariffs in his second term, experts said The consumer confidence index this month fell for a ninth consecutive month to its lowest level in 13 months, as global trade uncertainties and tariff risks cloud Taiwan’s economic outlook, a survey released yesterday by National Central University found. The biggest decline came from the timing for stock investments, which plunged 11.82 points to 26.82, underscoring bleak investor confidence, it said. “Although the TAIEX reclaimed the 21,000-point mark after the US and China agreed to bury the hatchet for 90 days, investors remain worried that the situation would turn sour later,” said Dachrahn Wu (吳大任), director of the university’s Research Center for
Alchip Technologies Ltd (世芯), an application-specific integrated circuit (ASIC) designer specializing in artificial-intelligence (AI) chips, yesterday said that small-volume production of 3-nanometer (nm) chips for a key customer is on track to start by the end of this year, dismissing speculation about delays in producing advanced chips. As Alchip is transitioning from 7-nanometer and 5-nanometer process technology to 3 nanometers, investors and shareholders have been closely monitoring whether the company is navigating through such transition smoothly. “We are proceeding well in [building] this generation [of chips]. It appears to me that no revision will be required. We have achieved success in designing
PROJECTION: KGI Financial said that based on its foreign exchange exposure, a NT$0.1 increase in the New Taiwan dollar would negatively impact it by about NT$1.7 billion KGI Financial Holding Co (凱基金控) yesterday said its life insurance arm has increased hedging and adopted other moves to curb the impact of the local currency’s appreciation on its profitability. “It is difficult to accurately depict the hedging costs, which might vary from 7 percent to 40 percent in a single day,” KGI Life Insurance Co (凱基人壽) told an investors’ conference in Taipei. KGI Life, which underpinned 66 percent of the group’s total net income last year, has elevated hedging to 55 to 60 percent, while using a basket of currencies to manage currency volatility, the insurer said. As different
Taiwanese insurers are facing difficult questions about the damage of recent swings in the New Taiwan dollar. Regulators might have a partial solution: letting firms change how they calculate the value of foreign currency assets. The Financial Supervisory Commission (FSC) is considering allowing insurers to use six-month average exchange rates when they calculate risk-based capital in their semiannual reports, a shift from the current system where insurers use exchange rates on the final day of reporting. The change could ease pressure on the US$1.2 trillion insurance sector, whose huge exposure to foreign assets came into the spotlight earlier this month after a
RSS